glp 1 agonist with dpp 4 inhibitor The DPP-4 linagliptin and the GLP-1 receptor exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose DPP-4 inhibitors and GLP-1RAs: cardiovascular

The study by Riley et al., despite its retrospective design, represents the largest dataset to date, offering robust evidence on cardiovascular and renal outcomes associated with this therapeutic strategy (106)

Weeks 3-6: Building Momentum This is when most people start noticing meaningful improvements

Chen L, Park JS, Wu D, Kim CH, Yoon J

10 mg vial + 2 mL BAC water: Concentration = 5 mg/mL 1.75 mg dose = 35 units (0.35 mL) on a 100-unit insulin syringe 2 mg dose = 40 units (0.40 mL) on a 100-unit insulin syringe Doses per vial: ~5 doses at 2 mg, or ~5 doses at 1.75 mg Supplies Needed 12 vials PT-141 (10 mg each) provides 510 doses per vial at standard dosing 1 vial bacteriostatic water (30 mL) Insulin syringes (2931 gauge, 100-unit) Alcohol prep pads Administration Injection Technique PT-141 is administered via subcutaneous (SubQ) injection

320 , G1093g1104 (2021)